Iowa Senate Bill SF307

Iowa 2023-2024 Regular Session

• Introduced: 2/15/23
• Refer: 2/15/23

Caption

A bill for an act relating to step therapy protocols and interchangeable biosimilars.

Impact

The bill amends several provisions in the state code to clarify definitions related to biological products and biosimilars, ensuring that patients can be required to try these alternatives before being prescribed brand-name drugs. This legislative change is expected to spur greater adoption of biosimilars, leading to possible reductions in the cost of medications and promoting their availability in the healthcare marketplace. Furthermore, it aligns state law with federal regulations surrounding biological products, thereby streamlining the process for patient care and insurance practices.

Summary

Senate File 307, introduced by Senator Alons, proposes modifications to the state's approach to step therapy protocols and the regulation of interchangeable biosimilars. The bill aims to enhance patient access to prescription medications by allowing health carriers and utilization review organizations to implement step therapy that includes interchangeable biosimilars in addition to generic and biological products. This adjustment reflects a growing recognition of the importance of biosimilars as equivalent alternatives to branded drugs, enhancing competition and potentially reducing healthcare costs for patients.

Contention

Notably, there are potential points of contention that may arise surrounding the implementation of step therapy protocols for biosimilars. While proponents of SF307 argue that it will facilitate better access to life-saving medications, some healthcare professionals and patient advocates may express concerns about the appropriateness of mandated step therapy, particularly for patients with complex health conditions. Critics may question whether step therapy could impose unnecessary burdens on patients, delaying the acquisition of essential medications. It is essential for stakeholders to balance patient access and safety against the goals of cost reduction and market efficiency.